Two candidate blood biomarkers tied to mitochondrial dynamics in Parkinson's — from public gene data, not yet a test

Edited by Samael A. Tejada, Founder & Editor-in-Chief

An early Parkinson's test would change the disease's timeline — earlier confirmation, earlier trials, earlier planning. This study does the honest first part of that work: it nominates candidates, in public, with its methods exposed.

How were the candidates found?

The team integrated transcriptomic data from the Gene Expression Omnibus — a training set (GSE6613, n=72) and a larger validation set (GSE99039, n=438) — with a panel of 23 genes related to mitochondrial dynamics, the processes governing mitochondrial shape, movement and quality control. From that integration they derived a mitochondrial-dynamics score and identified the genes whose expression correlated with it and separated Parkinson's samples: CYSLTR2 and TTPAL. Follow-up RT-qPCR measurement suggested the same directions in patients — CYSLTR2 downregulated, TTPAL upregulated, at P less than 0.0001.

Why these two genes are interesting

Neither is a classic mitochondrial gene, which is the point of a dynamics-score screen. CYSLTR2 encodes a receptor for cysteinyl leukotrienes — inflammatory lipid mediators — connecting the signal to neuroinflammation, a parallel Parkinson's pathway. TTPAL relates to alpha-tocopherol (vitamin E) transfer, connecting it to antioxidant handling, a long-standing mitochondrial-stress theme. If either association replicates, the value is twofold: a measurable blood signal, and a mechanistic thread — inflammation or antioxidant transport interacting with mitochondrial dynamics — that experiments can pull on.

What stands between a candidate and a test?

Almost everything that makes a test trustworthy. GEO datasets are retrospective, assembled from earlier studies with their own collection and processing differences; a score that separates those samples must still separate newly recruited patients, early-stage patients, and patients with look-alike conditions, in pre-registered prospective cohorts, with a locked assay and cut-off. The authors claim none of that: their conclusion is that CYSLTR2 and TTPAL are candidate biomarkers providing targets for mechanistic investigation and therapeutic exploration. Readers offered a commercial 'mitochondrial Parkinson's test' today should ask which of those validation steps it has passed — for these candidates, that work is ahead, not behind.

Where the evidence stands

• Established: Mitochondrial dynamics dysfunction is implicated in Parkinson's biology, and Parkinson's lacks a specific early diagnostic biomarker — the gap this work addresses.
• Preliminary: CYSLTR2 and TTPAL as biomarkers: identified by dataset integration (n=72 training; n=438 validation) with RT-qPCR expression support in one study (PLoS One, 2026). No prospective or clinical validation exists.
• Absent: A usable test. No locked assay, diagnostic cut-off, sensitivity/specificity in early or differential diagnosis, or regulatory evaluation has been reported.